Handelsbanken Fonder AB Increases Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Handelsbanken Fonder AB lifted its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 27.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 81,900 shares of the company’s stock after acquiring an additional 17,500 shares during the quarter. Handelsbanken Fonder AB’s holdings in TransMedics Group were worth $5,106,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Quarry LP lifted its holdings in TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after buying an additional 312 shares in the last quarter. National Bank of Canada FI increased its position in shares of TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after purchasing an additional 262 shares during the last quarter. Farther Finance Advisors LLC grew its position in shares of TransMedics Group by 187.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after buying an additional 316 shares during the last quarter. Hager Investment Management Services LLC bought a new stake in shares of TransMedics Group during the 4th quarter valued at about $33,000. Finally, Sachetta LLC bought a new stake in shares of TransMedics Group during the 4th quarter valued at about $40,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insider Transactions at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 7.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Canaccord Genuity Group lowered their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Oppenheimer reaffirmed an “outperform” rating and set a $125.00 price objective on shares of TransMedics Group in a research report on Tuesday, December 3rd. Robert W. Baird decreased their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Finally, TD Cowen decreased their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Trading Down 4.6 %

Shares of NASDAQ:TMDX opened at $71.95 on Monday. The company has a 50 day moving average of $66.63 and a 200-day moving average of $104.16. The firm has a market cap of $2.41 billion, a P/E ratio of 76.54 and a beta of 2.12. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.